Zheng Quan Shi Bao Wang·2025-09-25 10:54Core Insights - The article highlights the official launch of Tafasitamab (Minokai), a CD19 monoclonal antibody, in China for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), marking a significant milestone for the company and the industry [1][12]. Group 1: Product Launch and Significance - Tafasitamab is the first and only CD19 monoclonal antibody approved for treating lymphoma globally and the first in China for R/R DLBCL, filling a critical gap in targeted therapy for this condition [1][2]. - The rapid prescription of Tafasitamab across multiple provinces in China signifies its clinical application and the company's commitment to improving patient access to innovative therapies [1][12]. Group 2: Clinical Need and Patient Demographics - DLBCL accounts for 31%-34% of non-Hodgkin lymphoma (NHL) cases globally, with a higher prevalence in China at 45.8% of all NHL cases [2]. - Approximately 30%-40% of patients face recurrence or treatment resistance after first-line therapy, indicating a significant unmet clinical need for effective second-line treatments [2][3]. Group 3: Treatment Efficacy and Benefits - Tafasitamab, in combination with Lenalidomide, has shown a high overall response rate (ORR) of 67.5% and a complete response (CR) rate of 52.5% in R/R DLBCL patients, demonstrating its potential for deep remission [5][7]. - The five-year overall survival (OS) rate for patients treated with Tafasitamab is promising, with a median OS of 33.5 months reported, indicating long-term benefits [7][8]. Group 4: Safety and Tolerability - Tafasitamab has a favorable safety profile compared to traditional chemotherapy, with lower incidence and severity of adverse events, making it more tolerable for patients, especially the elderly [10][12]. - The drug's mechanism of action through immune effects provides a new non-chemotherapy treatment option for patients who are not suitable for transplantation [10][12].